Gonadorelin (GnRH): Fertility and Testosterone Evidence

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the ten-amino-acid decapeptide that the hypothalamus secretes in precisely timed pulses to activate the entire reproductive axis covered in our peptide science hub ^[2]. Each pulse reaches the anterior pituitary and triggers the release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone); those gonadotropins then drive testosterone production and spermatogenesis in men, or follicular development and ovulation in women ^[1]. What makes gonadorelin pharmacologically unusual is that the same molecule has the opposite effect depending on how it is delivered: pulsatile administration stimulates the reproductive axis; continuous or high-frequency delivery desensitizes the pituitary and shuts the axis down — the very mechanism GnRH agonists like leuprolide exploit to suppress testosterone in prostate cancer ^[1][2]. Unlike upstream hypothalamic regulators such as kisspeptin, which paces the GnRH pulse generator itself, gonadorelin acts as the pulse signal. Unlike the growth-axis peptides analyzed in the sermorelin vs. GH evidence review, gonadorelin targets the reproductive axis entirely. And unlike PT-141/bremelanotide, which acts on melanocortin receptors for sexual function, gonadorelin’s mechanism is hormonal signaling rather than central arousal. This article separates three distinct evidence tiers: a genuine, pump-validated evidence base in GnRH-deficiency states and hypothalamic amenorrhea; a well-established diagnostic role as a pituitary stimulation test; and a contemporary off-label compounded use as an hCG alternative in testosterone replacement therapy — a use with strong mechanistic plausibility but no dedicated controlled trial data.

How gonadorelin works: pulsatile GnRH and the HPG axis

The hypothalamic–pituitary–gonadal (HPG) axis is governed by a pulse generator in the hypothalamic arcuate nucleus that releases GnRH in discrete bursts — approximately once every 60–90 minutes in adult men, with the frequency varying across the menstrual cycle in women ^[2]. Each burst lasts seconds to minutes and drives a corresponding pulse of LH from the pituitary. When Wildt and colleagues delivered pulsatile GnRH via infusion pump at 1 pulse/hour in rhesus monkeys with suppressed gonadotropin levels, sustained LH and FSH secretion was restored ^[1]. When they then increased the delivery frequency to 2, 3, or 5 pulses/hour — keeping the total GnRH dose constant — plasma gonadotropin concentrations declined progressively ^[1]. The pituitary was not responding to more frequent GnRH with more LH; it was responding with less. This frequency-dependent suppression is the physiological basis for the paradox at the heart of GnRH pharmacology.

Amplitude matters as much as frequency. In the same experimental series, reducing the infusion rate from 1 μg/min to 0.1 μg/min caused LH and FSH to fall to immeasurable levels; an intermediate rate of 0.5 μg/min produced unstable, variable gonadotropin responses ^[1]. The practical implication for compounded gonadorelin is that both dose and timing must be controlled to replicate the physiological signal. A brief subcutaneous injection once or twice daily — the typical compounded protocol used in testosterone replacement clinics — produces a pharmacological spike followed by rapid clearance, which is structurally different from the precision-pump pulsatile delivery used in the clinical trials.

The pulsatile vs. continuous paradox: why the same molecule can suppress or stimulate

Continuous or high-frequency GnRH receptor stimulation produces what Conn and Crowley described as “paradoxical desensitization of pituitary gonadotropin secretion,” resulting in “complete ablation of the reproductive axis” ^[2]. This is not a side effect of GnRH agonists — it is their intended mechanism. Leuprolide, goserelin, and nafarelin are synthetic GnRH analogs engineered to resist enzymatic degradation, giving them long plasma half-lives. When administered by depot injection or implant, they maintain continuous high-level GnRH-receptor stimulation, which drives receptor internalization and down-regulation, collapses LH and FSH secretion, and suppresses gonadal hormone production to castrate levels ^[2]. This is exploited therapeutically in prostate cancer, endometriosis, precocious puberty, and IVF down-regulation protocols.

Native gonadorelin, by contrast, has a plasma half-life measured in minutes ^[2]. Endopeptidases in plasma and pituitary tissue rapidly cleave the decapeptide at multiple sites, inactivating it. This brevity is physiologically appropriate: the hypothalamic pulse generator produces brief bursts precisely so each pulse creates a discrete LH spike followed by receptor recovery, preventing desensitization. It is also why the FDA-approved Factrel formulation was used purely as a diagnostic stimulus — a bolus injection that provokes a brief LH/FSH surge to test pituitary reserve, without the prolonged receptor stimulation that would induce down-regulation. Therapeutic applications that aim to genuinely replace the pulsatile GnRH signal require a programmable infusion pump, not a simple injectable schedule.

Historical FDA-approved products: Factrel, Lutrepulse, and what they actually treated

Two distinct FDA-approved gonadorelin products existed in the United States, serving fundamentally different clinical purposes. Factrel (gonadorelin hydrochloride, Wyeth-Ayerst) was approved for a single diagnostic indication: the GnRH stimulation test, in which a bolus IV or SC dose of gonadorelin is administered and serial LH (and sometimes FSH) measurements are taken over 120 minutes to assess anterior pituitary reserve. A blunted or absent LH response indicates pituitary disease; a normal LH rise indicates the problem originates in the hypothalamus. Factrel was never approved for any therapeutic indication — not for fertility, not for testosterone support, not for anti-aging or wellness.

Lutrepulse (gonadorelin acetate, Ortho Pharmaceutical) was a separate product: a lyophilized gonadorelin formulation packaged with a programmable infusion pump that delivered precisely timed SC or IV pulses every 90 minutes at 2.5–20 μg/pulse. The FDA approved Lutrepulse specifically for the induction of ovulation in women with primary hypothalamic amenorrhea — a condition caused by absent or insufficient pulsatile GnRH secretion. Lutrepulse was also used clinically in men with GnRH-deficient hypogonadism (idiopathic hypogonadotropic hypogonadism, Kallmann syndrome) to restore gonadotropin secretion, testosterone production, and fertility. Both Factrel and Lutrepulse were commercially discontinued — not for safety or effectiveness reasons, but for market factors. No FDA-approved gonadorelin product currently exists; all available gonadorelin is compounded.

Where the evidence is real: GnRH deficiency, fertility, and hypothalamic amenorrhea

The strongest evidence for gonadorelin comes from patients who lack functional GnRH secretion — the population for which the Lutrepulse pump was designed. In these patients, pulsatile GnRH replacement is physiological substitution for a missing hypothalamic signal, not a pharmacological augmentation of a functioning axis.

• IHH / Kallmann syndrome in men — Kliesch et al. 1994 ^[3]: A controlled clinical trial in 26 men across 33 treatment cycles. Sperm appeared in the ejaculate in 30 of 33 cycles; pregnancies were achieved in 15 of 18 couples attempting conception; serum testosterone normalized; testicular volumes increased significantly. Pregnancies occurred even with sperm counts below the normal range, and efficacy was comparable between pulsatile GnRH and gonadotropin therapy.
• IHH in men — Pitteloud et al. 2002 ^[4]: The largest published prospective series: 76 IHH men, 12–24 months of pulsatile GnRH therapy initiated at 5–25 ng/kg/pulse SC and titrated to normalize testosterone. LH normalized in 97% of participants, testosterone in 93%, FSH in 96%, and inhibin B in 93%. Independent predictors of better spermatogenesis outcomes were prior pubertal development (positive predictor), baseline inhibin B >60 pg/ml (positive predictor), and absence of cryptorchidism.
• Comparative therapy in GnRH-deficient men — Pitteloud & Dwyer 2014 ^[5]: A review comparing pulsatile GnRH pump, hCG alone, and sequential FSH-then-GnRH-pump approaches in hypogonadotropic hypogonadal men. A 13-patient trial within the review found that a sequential FSH-then-pump protocol achieved 100% sperm in the ejaculate, while the comparator arm left 33% of men (2 of 6) azoospermic. The authors call for a large multicenter randomized trial to establish the optimal protocol.
• Functional hypothalamic amenorrhea — Quaas et al. 2022 ^[6]: A 25-year cohort (1996–2020) treated 66 women with functional hypothalamic amenorrhea (FHA) using pulsatile GnRH every 90 minutes across 82 treatment courses and 212 ovulation-induction cycles. Ovulation rate was 96%; monofollicular ovulation occurred in 75% of cycles; biochemical pregnancy rate was 80.5%; clinical pregnancy rate was 74.4%; live birth rate was 65.9% per treatment; miscarriage rate was 11.5%; and the multiple-pregnancy rate was just 1.6% — substantially lower than with injectable gonadotropins. The authors concluded that pulsatile GnRH is “a safer and more physiologic alternative to ovulation induction with injectable gonadotropins.”
• Hypothalamic amenorrhea — Christou, Pitteloud & Gomez 2017 ^[7]: A case series of 12 patients (1 Kallmann syndrome, 4 normosmic isolated hypogonadotropic hypogonadism, 7 FHA) treated with pulsatile GnRH at 90-minute intervals, either IV (5 μg/pulse) or SC (15 μg/pulse). All 12 achieved ovulation; single ovulation occurred in 30 of 33 cycles regardless of administration route; 10 pregnancies resulted across 7 patients.

Compounded gonadorelin in TRT clinics: the hCG alternative rationale

Exogenous testosterone suppresses the HPG axis through negative feedback, driving LH and FSH to undetectable levels. The key clinical consequence is that intratesticular testosterone (ITT) — the concentration of testosterone inside the testes required to support spermatogenesis — collapses, even when serum testosterone is normal or elevated from injected or topical testosterone. Coviello and colleagues demonstrated this precisely in a 2005 randomized controlled trial: at baseline, ITT was 1,174 nmol/liter while serum testosterone was only 14.1 nmol/liter — an approximately 83-fold intratesticular gradient maintained by the Leydig cells' proximity to LH-driven local production ^[8]. When 200 mg testosterone enanthate per week was given with placebo, LH was suppressed by 95%, FSH by 97%, and ITT plummeted by 94% — from a baseline of 1,234 to 72 nmol/liter — while serum testosterone rose as expected ^[8].

Human chorionic gonadotropin (hCG) is an LH analog that acts directly on testicular Leydig cell LH receptors, bypassing the pituitary. In the Coviello RCT, adding low-dose hCG to the testosterone regimen maintained ITT in a dose-dependent manner: 125 IU every other day kept ITT 25% below baseline; 250 IU was 7% below; 500 IU was 26% above baseline ^[8]. Ramasamy and colleagues concluded in a review that hCG “has shown the ability not only to reverse azoospermia brought on by testosterone supplementation therapy but also to help maintain elevated intratesticular testosterone levels” ^[9]. For years, hCG co-administration became a standard adjunct for clinics wanting to preserve testicular size and fertility potential during TRT.

In 2020 the FDA issued guidance restricting the large-scale compounding of hCG, which pushed many compounding pharmacies to offer gonadorelin as an upstream alternative. The mechanistic logic: if pulsatile gonadorelin can stimulate the pituitary to release LH pulses, those pulses will in turn stimulate Leydig cells, maintaining ITT during exogenous testosterone therapy. This is physiologically plausible, but no published randomized controlled trial has tested this hypothesis in men receiving exogenous testosterone. The compounded SC gonadorelin protocols used in wellness clinics — typically 100–250 μg once or twice daily — are not the precision-pump pulsatile protocols used in GnRH-deficiency trials. No human PK/PD study has confirmed that these SC injections produce physiologically effective LH pulses in T-suppressed men. The compounding context is regulatory and logistical; the evidence transfer is not.

Half-life, dosing burden, and the pump vs. injection gap

Native gonadorelin is inactivated within minutes of entering plasma, degraded by endopeptidases at multiple cleavage sites on the decapeptide chain ^[2]. This brevity is physiologically intentional: the hypothalamic pulse generator produces brief bursts so each pulse creates a discrete LH spike followed by receptor recovery, preventing desensitization. Therapeutically, the short half-life creates a delivery challenge that the Lutrepulse pump solved by administering controlled pulses at 90-minute intervals around the clock, exactly replicating the hypothalamic rhythm. The clinical trial evidence reviewed above was obtained with this pump system.

Compounded gonadorelin as currently dispensed in TRT clinics is a subcutaneous injectable administered by the patient once to three times daily. This is pharmacologically different from the pump protocol in two key respects. First, the interval between injections is far longer than 90 minutes, so stimulatory signals reach the pituitary only at injection times. Second, each SC injection delivers a bolus that may briefly exceed, then rapidly fall below, the threshold for effective LH stimulation — creating a spike-and-crash pattern rather than a sustained pulsatile rhythm. Whether this translates to clinically meaningful LH and ITT support in men receiving exogenous testosterone has not been quantified. The field lacks the human PK/PD studies that would at minimum establish what a given compounded SC dose actually does to LH in this population.

Evidence summary across gonadorelin uses

Safety considerations

• Injection-site reactions: The most commonly reported adverse effect in clinical trials is local injection-site discomfort, redness, and swelling at the SC injection site. In Lutrepulse pump trials, device-related reactions at the infusion catheter site were the primary tolerability issue.
• Ovarian hyperstimulation syndrome (OHSS) in women: A theoretical risk with any ovulatory stimulus. Pulsatile GnRH strongly favors monofollicular ovulation — 75% of cycles in the Quaas 25-year cohort ^[6] — making OHSS far less common than with injectable gonadotropin protocols.
• Multiple pregnancy: Risk is substantially lower with pulsatile GnRH than with exogenous gonadotropins; the Quaas 25-year cohort reported a 1.6% multiple-pregnancy rate ^[6], reflecting the physiologic single-follicle recruitment characteristic of the treatment.
• Hormonal fluctuations in men on TRT: If compounded gonadorelin successfully stimulates LH in a TRT patient and raises intratesticular testosterone, the combined effect with exogenous testosterone could transiently elevate total and free testosterone, affecting estradiol, hematocrit, and other monitored parameters. This interaction has not been systematically studied in the compounded SC setting.
• Short-term safety in GnRH-deficiency trials: The clinical trial record for pump-delivered pulsatile GnRH in IHH, Kallmann, and FHA populations is reassuring; no serious systemic adverse events attributable to gonadorelin have emerged from these trials ^[3][4][6]. Long-term safety data in healthy adults using compounded SC protocols are not available.
• Compounded-preparation quality risk: No FDA-approved gonadorelin product currently exists. All available gonadorelin is compounded, without the manufacturing controls, sterility verification, or potency testing of an approved drug. Compounded preparations are subject to USP <797> pharmacy standards but not to FDA's pre-market review.